Note: Pfizer funded.
Real-world effectiveness of 20-valent pneumococcal conjugate vaccine against all-cause outcomes among Medicare beneficiaries aged 65 years and older in the USA: a retrospective cohort study
https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(26)00115-5/abstract
“PCV20 vaccination was associated with a lower risk of all invasive pneumococcal disease, all pneumococcal pneumonia, all-cause pneumonia, and LRTI among adults aged 65 years or older in the USA compared with no PCV20 vaccination.”